Document is current
Any future updates will be listed below
-
Authors
Lim, Jennifer I.
Ko, Stella
McAllister, Mark
Faux, Nancy
Bawa, Komal
Mearns, Elizabeth
Patel, Shriji
Spicer, Galin https://orcid.org/0009-0000-4423-582X
Martinez, Amanda https://orcid.org/0009-0009-3476-7019
Tabano, David https://orcid.org/0000-0001-7657-0809
-
Funding
Funding for this research was provided by:
Genentech (N/A)
- License Information
-
More Information
Article History
Received: 18 November 2024
Revised: 16 April 2025
Accepted: 29 April 2025
First Online: 15 May 2025
Competing interests
: The authors made the following disclosures: J.I.L.: Consultant/Advisor – AbbVie/Allergan, Alimera, Astellas/Iveric Bio, Aura, Cognition, Eyenuk, EyePoint, Genentech/Roche, Luxa, Novartis, Regeneron, Unity, Viridian; Grant Support – Adverum, Aldeyra, BioSpring Vision, Genentech, Inc., Graybug, Janssen, Kyoto Drug Development, NGM Bio, Regeneron, Regenex, Stealth; Honoraria: Bausch + Lomb, Iveric Bio; S.K.: Employee – Genentech, Inc.; K.B.: Employee – Genentech, Inc.; E.M.: Employee – Genentech, Inc.; S.P.: Employee – Genentech, Inc.; G.S.: Employee – Genentech, Inc.; D.T.: Employee – Genentech, Inc. The other authors have no proprietary or commercial interest in any materials discussed in this article.
